)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
WuXi AppTec
WuXi AppTec (603259) investor relations material
WuXi AppTec Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary26 Oct, 2026
Executive summary
9M revenue reached RMB45.54bn, up 38.6% YoY; Continuing Operations revenue grew 46.3%, and backlog rose 36.4% to RMB76.74bn at Sept. 30.
Adjusted non-IFRS net profit increased 74.4% to RMB18.38bn.
FY2026 revenue and Continuing Operations growth guidance were raised, alongside higher adjusted free cash flow guidance.
Financial highlights
Q3 revenue was RMB16.64bn, up 38.0% YoY; attributable net income rose 136.7% to RMB8.32bn, including substantial disposal gains.
9M CAS net profit was RMB19.40bn, up 60.6%; net profit after non-recurring items was RMB16.48bn, up 73.0%.
9M adjusted non-IFRS net profit reached RMB18.38bn, up 74.4%; adjusted EPS was RMB6.31 versus RMB3.71.
9M operating cash flow increased 50.7% to RMB17.19bn; adjusted operating cash flow was RMB17.28bn, up 58.9%.
9M total profit was RMB24.05bn, up 59.9% YoY.
Outlook and guidance
FY2026 revenue guidance rose to RMB61.0–61.9bn from RMB58.5–60.5bn; Continuing Operations growth guidance increased to 40–42% from 35–39%.
FY2026 TIDES revenue is expected to grow ~47% YoY; adjusted non-IFRS net profit margin is expected to remain stable and resilient.
FY2026 capex guidance is RMB8.0–8.5bn; adjusted free cash flow guidance rose to RMB14.5–15.5bn from RMB13.5–14.5bn.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from WuXi AppTec
- H1 2026 saw record revenue, profit, and margin growth, with upgraded full-year outlook.603259
Q2 2026 - Q1 2026 revenue and profit surged, led by chemistry and CRDMO segment growth.603259Q1 2026
- Record revenue and profit in 2025; 2026 guidance targets 18–22% growth and strong cash flow.603259H2 2025
- Record 2025 results, robust pipeline, and major capacity expansions drive sustained growth.60325944th Annual J.P. Morgan Healthcare Conference
- Net profit more than doubled on strong CRDMO growth, margin gains, and asset sale gains.603259H1 2025
- Q3 revenue rose sequentially, with TIDES growth and robust backlog despite profit decline.603259Q3 2024
- H1 2024 revenue fell, but Q2 rebounded and TIDES grew 57.2%, with strong full-year guidance.603259H1 2024
- Record Q4 and strong 2024 set stage for double-digit growth in 2025.603259H2 2024
- Integrated CRDMO model, innovation, and ESG drive strong growth and resilience in 2024.60325943rd Annual J.P. Morgan Healthcare Conference 2025
Next WuXi AppTec earnings date
Q4 202615 Mar, 2027
WuXi AppTec
Next WuXi AppTec earnings date
Q4 202615 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
WuXi AppTec Co. Ltd is a global pharmaceutical and healthcare services company based in Shanghai, China. It provides a wide range of research, development, and manufacturing services tailored to the pharmaceutical, biotech, and medical device industries. Its offerings span across various areas including small molecule drugs, cell therapies, and gene therapies, as well as medical device testing. The company is headquartered in Shanghai, China, and its shares are listed on the Hong Kong Stock Exchange.